Editor’s note: The ibogaine Investigator’s Brochure discussed here was published by MAPS, where Ali is co-executive director.
Two years have passed since the Food and Drug Administration’s decision not to approve MDMA-assisted therapy for PTSD, and the U.S. government could be ready to shift its position and accelerate psychedelic medicine instead of playing the villain it has been for the last fifty years. The zeitgeist surrounding ibogaine offers critical insight into the perils and promise of this moment.
By directing Health and Human Services to allocate $50 million to match states’ investment in psychedelic research, creating novel priority regulatory pathways for “breakthrough” psychedelic treatments, and directing agencies to accelerate access through multiple administrative channels, the April 2026 Executive Order and subsequent cascade of agency actions are the clearest evidence that at least one branch of the federal government is on board with the momentum to medicalize psychedelics.
Curiously, the EO specifically named ibogaine as a potential beneficiary of both Right to Try laws and regulatory favoritism, despite it not yet qualifying for either. The order cites serious mental illness and veteran suicide statistics that, however real, are not themselves evidence that ibogaine works. Ibogaine also carries a well documented cardiac risk, including QT prolongation, that has made it a harder regulatory case than psilocybin or MDMA. Put simply, the White House naming a specific, unapproved molecule for expedited treatment ahead of its own agencies’ findings raises a fair question about whether these reforms are driven by evidence or political expediency. Somehow, the most complex molecule in the contemporary psychedelic pantheon has found itself at the center of an appropriately complex political moment.
While it seemed to happen out of nowhere, the EO actually followed years of slow but steady signals. In 2021, the National Institutes of Health issued a grant to research psychedelic treatment, its first in 50 years to evaluate a Schedule I substance’s therapeutic potential instead of its risks or harms. In 2024, the Government Accountability Office published a report calling on the Drug Enforcement Administration to resolve obstacles to its existing religious exemption process ostensibly created as a pathway to petition for permission to utilize psilocybin mushrooms and other controlled substances as sacraments. In February of this year, the FDA announced that it would default to only requiring one instead of two Phase III clinical trials for new drug applications. As of today, tens of millions of dollars have been allocated by Congress for psychedelic studies within the Veterans Administration and Department of Defense. In this more comprehensive context, the EO comes as less of a surprise and, for supporters of medical access, appears to be a decisive step in the right direction (pun intended).
The political cover provided by the EO and the underlying advocacy that informed it have both come from and clearly penetrated to the states. Last year Texas set aside $50 million for ibogaine clinical trials, and conditioned the money on a matching $50 million from a private partner. When it became clear that early proposals from drug companies would not align with state requirements, officials announced Texas would supply the match itself. In June, Colorado established an ibogaine research pilot program that can include up to five pilot sites, and several additional states passed bills about ibogaine in the 2026 legislative session.
Less than two weeks before Governor Jared Polis signed HB 26-1325, Gabon issued Decree No. 0239/PR, affirming the national heritage and strategic role of iboga and its chemical derivatives, including ibogaine. The action mandated authorization from the Ministry of Culture, following binding review by a new interministerial commission, for any research, export, or commercial activity involving the plant. Iboga grows in Gabon, and communities across the Congo Basin have steered and stewarded its ceremonial and healing use for generations, so it makes sense that the government has a stake in the matter.
However, it is unprecedented in the field of contemporary psychedelic medicine to see a government so experienced in navigating postcolonial dynamics, stewarding its natural resources, and managing the impact of outside interests on ecological, territorial, and traditional stakeholders. Investment follows patents, and knowledge that doesn’t readily yield intellectual property – such as the aforementioned practices honed in non-clinical, traditional, or unregulated settings – gets sidelined and tokenized. We’ve had decades to watch this happen with cannabis, and more recently with psilocybin and MDMA, but ibogaine could be on the fastest track yet.
These worldviews are worlds apart, and they exist within an ecosystem that can have space for both, until and unless commercial interest tips from enthusiasm to extraction. To level the playing field, MAPS, recently published an Investigator’s Brochure (IB) for ibogaine as an open-access resource, compiling known preclinical, safety, dosing, and observational data into a single document. IBs are normally expensive to produce and tightly held by pharmaceutical sponsors, so we made ours public to put it in reach of academics, nonprofits, community organizations, and other stakeholders impacted by but often left out of regulatory dialogue.
Practically speaking, it means that a researcher without industry backing can identify open questions faster, a policymaker can test claims made by advocates or companies against the scientific record, and organizations of all kinds can engage in the overall discourse without having to recreate a regulatory document. Translating and democratizing the kind of knowledge used to justify industry interest is one way we can keep advocacy honest.
The people whose knowledge and natural resources make a commercial product possible should participate in how that product is developed and who benefits from it. Anything short of that is plainly missing the point.
Government agencies, international clinics, academic researchers, Gabonese stakeholders, and people living with opioid use disorder or suffering from traumatic brain injury all have legitimate interests, and none of those interests are inherently incompatible. However, they will inevitably have to compete and undermine each other if the people and bodies responsible for building regulatory and policy frameworks – including commercial actors – fail to make space for all of them in the interest of expediency, profit, or the perception that one group’s suffering justifies treating others’ as externalities.
For now, the hype hasn’t abated. Congressional champions seek to codify EO 14401 with the aptly named Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy (IBOGAINE) Act. At the same time, the Food and Drug Administration is allowing an early-phase clinical study of noribogaine hydrochloride to proceed for the first time, and NIDA is backing an ibogaine study at Harvard to the tune of $11M.
The instinct in some corners of the commercial ecosystem is to route around Gabonese interests by using synthetic ibogaine or analogs like noribogaine, or by treating it as someone else’s problem. Indeed, all of this momentum is happening in the shadow of the Trump administration’s ongoing restriction of Gabonese visas into the United States. However, this dynamic presents supply chain and stewardship problems that do not disappear just because some prefer not to look at them.
A framework that ignores the Gabonese government and peoples’ interests, the iboga plant’s ecological constraints, and the cultural knowledge embedded in territory-based traditions is fragile, incomplete, and risks undermining its own healing potential. On top of that, it will inevitably face regulatory, implementation, and reputational complications that a more accountable approach would not. Researchers, advocates, and sponsors have advocated for its promise since the 1960s and have tried to bring ibogaine into formal drug development since the 1990s. The work has stalled, restarted, and stalled again for reasons that have changed over the decades. This process is going to take however long it will take, and we might as well do it right the third time.
Frequently Asked Questions About Ibogaine Policy
This FAQ was prepared by Psychedelics Today and does not represent the author’s views.
Does Executive Order 14401 make ibogaine legal?
No. Ibogaine remains a Schedule I controlled substance under federal law. The April 2026 order directs agencies to accelerate research and to build access pathways, including under Right to Try, but it does not reschedule ibogaine or authorize treatment outside approved research.
What did Colorado’s ibogaine bill actually do?
HB 26-1325, signed June 4, 2026 and effective August 12, creates a research pilot program in the state’s Behavioral Health Administration authorizing up to five sites. Sites must work through the FDA’s investigational new drug process and establish benefit-sharing plans with Central African communities connected to iboga. The bill also tightened Colorado’s rules on non-commercial sharing of natural medicine, a provision now facing a repeal referendum effort.
What is Gabon’s iboga decree?
Decree No. 0239/PR of May 22, 2026 classifies iboga and its derivatives as national strategic heritage. Research, export, transformation, and commercial activity now require authorization from the ministry responsible for culture following binding review by an interministerial technical commission. The decree also creates a benefit-sharing mechanism and a sovereign iboga fund.
What is an Investigator’s Brochure?
An IB compiles the preclinical, safety, dosing, and observational data a sponsor submits to regulators to support human trials. They are expensive to produce and normally held privately by pharmaceutical sponsors. MAPS published its ibogaine Investigator’s Brochure as an open-access resource in July 2026.
Is ibogaine safe?
Ibogaine carries documented cardiac risk, including QT prolongation, which is why every regulated program built around it requires cardiac screening and monitoring. It has not completed the clinical trials needed to establish safety and efficacy for any indication, and no ibogaine product is FDA-approved.
